Literature DB >> 16618382

Gastric cancer: an update.

Manish A Shah1.   

Abstract

Gastric cancer is an aggressive malignancy, which, if metastatic or unresectable, is incurable. However, with metastatic or unresectable disease, patients receive a palliative benefit from chemotherapy. Although the understanding of the biology of this disease is increasing, the development of biologically targeted therapies for gastric cancer has been limited. Cytotoxic therapy remains the standard approach, and although there is agreement on the active agents and active combination chemotherapy regimens, consensus on the standard or reference regimen is lacking. This article reviews the pathophysiology of this disease, placing it in the context of its epidemiology, and the current advances in the treatment of this disease.

Entities:  

Mesh:

Year:  2006        PMID: 16618382     DOI: 10.1007/s11912-006-0018-4

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  47 in total

Review 1.  A systematic overview of chemotherapy effects in gastric cancer.

Authors:  K G Janunger; L Hafström; P Nygren; B Glimelius
Journal:  Acta Oncol       Date:  2001       Impact factor: 4.089

2.  Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy.

Authors:  Manish A Shah; David Ilson; David P Kelsen
Journal:  J Clin Oncol       Date:  2005-03-28       Impact factor: 44.544

3.  Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer.

Authors:  K Ridwelski; T Gebauer; J Fahlke; H Kröning; E Kettner; F Meyer; K Eichelmann; H Lippert
Journal:  Ann Oncol       Date:  2001-01       Impact factor: 32.976

4.  Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution's experience over 15 years.

Authors:  James C Yao; Jennifer F Tseng; Samidha Worah; Kenneth R Hess; Paul F Mansfield; Christopher H Crane; Isac I Schnirer; Satish Reddy; Silvia S Chiang; Azmeena Najam; Christina Yu; Geoffrey G Giacco; Keping Xie; Tsung-Teh Wu; Barry W Feig; Peter W T Pisters; Jaffer A Ajani
Journal:  J Clin Oncol       Date:  2005-05-01       Impact factor: 44.544

5.  Cancer statistics, 2005.

Authors:  Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2005 Jan-Feb       Impact factor: 508.702

6.  Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO).

Authors:  A D Roth; R Maibach; G Martinelli; N Fazio; M S Aapro; O Pagani; R Morant; M M Borner; R Herrmann; H Honegger; F Cavalli; P Alberto; M Castiglione; A Goldhirsch
Journal:  Ann Oncol       Date:  2000-03       Impact factor: 32.976

7.  A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Turkish Oncology Group.

Authors:  F Içli; I Celik; F Aykan; A Uner; A Demirkazik; A Ozet; M Ozgüroğlu; F Taş; H Akbulut; D Firat
Journal:  Cancer       Date:  1998-12-15       Impact factor: 6.860

8.  The intracellular E-cadherin germline mutation V832 M lacks the ability to mediate cell-cell adhesion and to suppress invasion.

Authors:  Gianpaolo Suriano; David Mulholland; Olivier de Wever; Paulo Ferreira; Ana Rita Mateus; Eric Bruyneel; Colleen C Nelson; Marc M Mareel; Jun Yokota; David Huntsman; Raquel Seruca
Journal:  Oncogene       Date:  2003-08-28       Impact factor: 9.867

9.  Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG).

Authors:  P Chollet; P Schöffski; K Weigang-Köhler; J H M Schellens; H Cure; N Pavlidis; V Grünwald; R De Boer; J Wanders; P Fumoleau
Journal:  Eur J Cancer       Date:  2003-06       Impact factor: 9.162

10.  Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).

Authors:  Atsushi Ohtsu; Yasuhiro Shimada; Kuniaki Shirao; Narikazu Boku; Ichinosuke Hyodo; Hiroshi Saito; Noboru Yamamichi; Yoshinori Miyata; Nobumasa Ikeda; Seiichiro Yamamoto; Haruhiko Fukuda; Shigeaki Yoshida
Journal:  J Clin Oncol       Date:  2003-01-01       Impact factor: 44.544

View more
  4 in total

1.  Could quantitative real-time polymerase chain reaction assay serve as an alternative test method to evaluate human epidermal growth factor receptor 2 status of gastric carcinoma in the South Asian setting?

Authors:  D K S Kannangara; M D S Lokuhetty; D Subasinghe; Y I N S Gunawardene; R S Dassanayake
Journal:  Indian J Gastroenterol       Date:  2019-08-10

2.  Prognostic significance of p53 protein expression in early gastric cancer.

Authors:  Andrea Rodrigues Gonçalves; Antonio Jose Vasconcellos Carneiro; Ivanir Martins; Paulo Antonio Silvestre de Faria; Maria Aparecida Ferreira; Eduardo Linhares Riello de Mello; Homero Soares Fogaça; Celeste Carvalho Siqueira Elia; Heitor Siffert Pereira de Souza
Journal:  Pathol Oncol Res       Date:  2010-11-30       Impact factor: 3.201

3.  The distinctive gastric fluid proteome in gastric cancer reveals a multi-biomarker diagnostic profile.

Authors:  Oi Lian Kon; Tai-Tung Yip; Meng Fatt Ho; Weng Hoong Chan; Wai Keong Wong; Soo Yong Tan; Wai Har Ng; Siok Yuen Kam; Alvin Kh Eng; Patrick Ho; Rosa Viner; Hock Soo Ong; M Priyanthi Kumarasinghe
Journal:  BMC Med Genomics       Date:  2008-10-25       Impact factor: 3.063

4.  Gene Expression Profiling of Gastric Cancer.

Authors:  Arivusudar Marimuthu; Harrys K C Jacob; Aniruddha Jakharia; Yashwanth Subbannayya; Shivakumar Keerthikumar; Manoj Kumar Kashyap; Renu Goel; Lavanya Balakrishnan; Sutopa Dwivedi; Swapnali Pathare; Jyoti Bajpai Dikshit; Jagadeesha Maharudraiah; Sujay Singh; Ghantasala S Sameer Kumar; M Vijayakumar; Kariyanakatte Veeraiah Veerendra Kumar; Chennagiri Shrinivasamurthy Premalatha; Pramila Tata; Ramesh Hariharan; Juan Carlos Roa; T S K Prasad; Raghothama Chaerkady; Rekha Vijay Kumar; Akhilesh Pandey
Journal:  J Proteomics Bioinform       Date:  2011-04-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.